CoChat

The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study

Open access

Published version of a preprint

The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.

Abstract

Brigimadlin (BI 907828) is an oral MDM2–p53 antagonist that has shown encouraging antitumor activity in vivo. We present phase Ia results from an open-label, first-in-human, phase Ia/Ib study investigating brigimadlin in patients with advanced solid tumors (NCT03449381). Fifty-four patients received escalating doses of brigimadlin on day 1 of 21-day cycles (D1q3w) or days 1 and 8 of 28-day cycles (D1D8q4w). Based on dose-limiting toxicities during cycle 1, the maximum tolerated dose was selected as 60 mg for D1q3w and 45 mg for D1D8q4w. The most common treatment-related adverse events (TRAE) were nausea (74.1%) and vomiting (51.9%); the most common grade ≥3 TRAEs were thrombocytopenia (25.9%) and neutropenia (24.1%). As evidence of target engagement, time- and dose-dependent increases in growth differentiation factor 15 levels were seen. Preliminary efficacy was encouraging (11.1% overall response and 74.1% disease control rates), particularly in patients with well-differentiated or dedifferentiated liposarcoma (100% and 75% disease control rates, respectively). Significance: We report phase Ia data indicating that the oral MDM2–p53 antagonist brigimadlin has a manageable safety profile and shows encouraging signs of efficacy in patients with solid tumors, particularly those with MDM2-amplified advanced/metastatic well-differentiated or dedifferentiated liposarcoma. Further clinical investigation of brigimadlin is ongoing. See related commentary by Italiano, p. 1765. This article is highlighted in the In This Issue feature, p. 1749

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/2159-8290.cd-23-0153

Cites

30 of 30 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Efficacy of brigimadlin in patients with advanced/metastatic solid tumors in phase Ia. Best change in size of target lesion from baseline in all patients enrolled to phase Ia.
Figure 1. Efficacy of brigimadlin in patients with advanced/metastatic solid tumors in phase Ia. Best change in size of target lesion from baseline in all patients enrolled to phase Ia.CC BY-NC-ND · PubMed Central
Figure 2. Efficacy in patients with WDLPS and DDLPS. A, Best change in the size of target lesion from baseline in patients with WDLPS. B, Time on treatment and progression-free survival (PFS) in patients with WDLPS. C, Best change in size of target lesion from baseline in patients with DDLPS. D, Time on treatment and PFS in patients with DDLPS. In C and D, the length of the bars indicates time on treatment and the shaded part of each bar indicates PFS. D, day.
Figure 2. Efficacy in patients with WDLPS and DDLPS. A, Best change in the size of target lesion from baseline in patients with WDLPS. B, Time on treatment and progression-free survival (PFS) in patients with WDLPS. C, Best change in size of target lesion from baseline in patients with DDLPS. D, Time on treatment and PFS in patients with DDLPS. In C and D, the length of the bars indicates time on treatment and the shaded part of each bar indicates PFS. D, day.CC BY-NC-ND · PubMed Central
Figure 3. Example patient scans showing responses and sustained disease stabilizations with brigimadlin. A, A 54-year-old female with a retroperitoneal MDM2-amplified WDLPS. The patient was heavily pretreated before being enrolled in the present trial, in which she received brigimadlin 20 mg q3w. The patient experienced a partial response (31% tumor reduction) starting at cycle 2. At cycle 10, the dose was reduced to 10 mg due to grade 2 neutropenia not recovering within 14 days. At cycle 19, a further tumor shrinkage (47% reduction) was observed. At cycle 29, the dose was further reduced to 5 mg due to grade 3 anemia. Treatment was finally discontinued after cycle 33 due to progressive disease. B, A 53-year-old female with a retroperitoneal MDM2-amplified WDLPS first diagnosed in July 2010 who, after four surgical resections, received doxorubicin for 6 cycles starting in March 2020 before progressing and being enrolled to the present trial. The patient received brigimadlin 80 mg D1q3w and experienced a partial response at cycle 3 (32% tumor reduction). The dose was reduced to 60 mg at cycle 4 due to neutropenia, to 50 mg at cycle 5 due to neutropenia, to 45 mg at cycle 8 due to thrombocytopenia, then to 30 mg at cycle 12 (December 2021) due to neutropenia, and finally to 20 mg at cycle 20 due to neutropenia. At data cutoff, the patient was ongoing in the study with a partial response (42% best tumor reduction, more than 25 months on treatment). C, A 65-year-old male with stage IV MDM2-amplified left perirenal DDLPS. Following previous treatment with adriamycin and olaratumab, followed by radiotherapy, the patient received brigimadlin 45 mg q3w. The patient achieved stable disease and stayed on treatment for nearly 2 years before experiencing progressive disease. D, A 51-year-old male with MDM2-amplified cholangiocarcinoma. Following 3 prior lines of therapy, he received brigimadlin 80 mg q3w, which was reduced to 45 mg q3w for 38 days in cycle 2 due to grade 4 thrombocytopenia and grade 4 neutropenia. The patient achieved a partial response by day 22, which was still evident on day 360; maximum tumor shrinkage was −73%. The patient remained on treatment for 13.3 months before experiencing progressive disease. B–D, The red arrows indicate the tumor sites. L, left; R, right.
Figure 3. Example patient scans showing responses and sustained disease stabilizations with brigimadlin. A, A 54-year-old female with a retroperitoneal MDM2-amplified WDLPS. The patient was heavily pretreated before being enrolled in the present trial, in which she received brigimadlin 20 mg q3w. The patient experienced a partial response (31% tumor reduction) starting at cycle 2. At cycle 10, the dose was reduced to 10 mg due to grade 2 neutropenia not recovering within 14 days. At cycle 19, a further tumor shrinkage (47% reduction) was observed. At cycle 29, the dose was further reduced to 5 mg due to grade 3 anemia. Treatment was finally discontinued after cycle 33 due to progressive disease. B, A 53-year-old female with a retroperitoneal MDM2-amplified WDLPS first diagnosed in July 2010 who, after four surgical resections, received doxorubicin for 6 cycles starting in March 2020 before progressing and being enrolled to the present trial. The patient received brigimadlin 80 mg D1q3w and experienced a partial response at cycle 3 (32% tumor reduction). The dose was reduced to 60 mg at cycle 4 due to neutropenia, to 50 mg at cycle 5 due to neutropenia, to 45 mg at cycle 8 due to thrombocytopenia, then to 30 mg at cycle 12 (December 2021) due to neutropenia, and finally to 20 mg at cycle 20 due to neutropenia. At data cutoff, the patient was ongoing in the study with a partial response (42% best tumor reduction, more than 25 months on treatment). C, A 65-year-old male with stage IV MDM2-amplified left perirenal DDLPS. Following previous treatment with adriamycin and olaratumab, followed by radiotherapy, the patient received brigimadlin 45 mg q3w. The patient achieved stable disease and stayed on treatment for nearly 2 years before experiencing progressive disease. D, A 51-year-old male with MDM2-amplified cholangiocarcinoma. Following 3 prior lines of therapy, he received brigimadlin 80 mg q3w, which was reduced to 45 mg q3w for 38 days in cycle 2 due to grade 4 thrombocytopenia and grade 4 neutropenia. The patient achieved a partial response by day 22, which was still evident on day 360; maximum tumor shrinkage was −73%. The patient remained on treatment for 13.3 months before experiencing progressive disease. B–D, The red arrows indicate the tumor sites. L, left; R, right.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 30 references

Research works printed but not linked: 1

  1. Rudolph, 2018, BI 907828: a novel, potent MDM2 inhibitor that is suitable for high-dose intermittent schedules [abstract]

Cited by

See all 108

Metadata

Authors
LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., & Gounder, M. M.
Affiliations
  • Yale Cancer Center (US)
  • National Cancer Centre Japan (JP)
  • Florida Cancer Specialists & Research Institute (US)
  • Ottawa Hospital (CA)
  • Sarah Cannon (US)
  • Boehringer Ingelheim (United States) (US)
  • Boehringer Ingelheim (Germany) (DE)
  • Memorial Sloan Kettering Cancer Center (US)
Corresponding author
Gounder, Mrinal M.
Venue
Cancer Discovery
Published
2023-06-03
Volume
13
Issue
8
Pages
1802-1813
ISSN
  • 2159-8274 (ISSN-L)
  • 2159-8290
OpenAlex
W4379259102
Cited by
101
References
29
Citations by year
2026: 21 · 2025: 35 · 2024: 41 · 2023: 4
FWCI
12.27
Type
journal article
Language
en
Open access
Locations
  • Cancer Discovery (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Boehringer Ingelheim (n/a)
Topics
  • Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Health Sciences › Medicine › Oncology › Sarcoma Diagnosis and Treatment
Keywords
brigimadlin, BI 907828, MDM2-p53 antagonist, p53, advanced solid tumors, metastatic solid tumors, liposarcoma, dedifferentiated liposarcoma, dose-limiting toxicity, maximum tolerated dose, growth differentiation factor 15, target engagement, oral anticancer drugs, treatment efficacy and safety
MeSH terms
Antineoplastic Agents, Heterocyclic Compounds, 4 or More Rings, Humans, Liposarcoma, Nausea, Neoplasms, Spiro Compounds, Tumor Suppressor Protein p53, Neoplasms, Second Primary, Proto-Oncogene Proteins c-mdm2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. https://app.cochat.ai/papers/10.1158/2159-8290.cd-23-0153
The paper
LoRusso, P., Yamamoto, N., Patel, M. R., Laurie, S. A., Bauer, T. M., Geng, J., Davenport, T., Teufel, M., Li, J., Lahmar, M., & Gounder, M. M. (2023). The MDM2-p53 antagonist brigimadlin (BI 907828) in patients with advanced or metastatic solid tumors: results of a phase Ia, first-in-human, dose-escalation study. Cancer Discovery. https://doi.org/10.1158/2159-8290.cd-23-0153

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.